Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arbutus Biopharma ( (ABUS) ) has provided an update.
Arbutus Biopharma Corporation announced the termination of two key executives, Karen Sims, Chief Medical Officer, and David Hastings, Chief Financial Officer, in March 2025. Both executives have entered into separation and consulting agreements with the company, allowing them to extend the exercise period of their stock options for up to a year post-termination. Additionally, Arbutus Biopharma is involved in a legal dispute with Moderna, Inc. over patent infringement related to Moderna’s COVID-19 vaccine, with the trial date moved to September 29, 2025.
More about Arbutus Biopharma
YTD Price Performance: 6.69%
Average Trading Volume: 904,305
Technical Sentiment Signal: Strong Sell
Current Market Cap: $666.4M
See more insights into ABUS stock on TipRanks’ Stock Analysis page.